Human Beta-defensin 1 in Vitiligo
Sponsor
Cairo University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03832751
Collaborator
(none)
25
2
9
Study Details
Study Description
Brief Summary
There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
25 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Estimation of Tissue Level of Human Beta-defensin 1 (HBD-1) in Vitiligo Before and After Narrowband UVB Phototherapy: a Case-control Study
Anticipated Study Start Date
:
Mar 1, 2019
Anticipated Primary Completion Date
:
Dec 1, 2019
Anticipated Study Completion Date
:
Dec 1, 2019
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: vitiligo patients Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy |
Other: skin biopsy before and after NB-UVB phototherapy
skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
|
| Active Comparator: Healthy controls Tissue levels of human beta-defensin 1 in healthy controls |
Other: skin biopsy before and after NB-UVB phototherapy
skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
|
Outcome Measures
Primary Outcome Measures
- Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy [6 months to 1 year]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
Patients with non-segmental vitiligo.
-
Both genders.
-
Age more than 18 years old.
-
New cases or cases not receiving any treatment for at least 3 months prior to the study.
Exclusion Criteria:
-
Universal or segmental vitiligo.
-
Any contraindication to phototherapy treatment.
-
History of autoimmune diseases or other systemic diseases.
-
Any other skin disease.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Cairo University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Maha Fathy Elmasry,
principal investigator,
Cairo University
ClinicalTrials.gov Identifier:
NCT03832751
Other Study ID Numbers:
- Dermatology 12
First Posted:
Feb 6, 2019
Last Update Posted:
Feb 6, 2019
Last Verified:
Feb 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: